Structure-activity insights into benzimidazole-based Ir(III) cyclometallated complexes for cancer therapy

Area of Science:

• Coordination Chemistry
• Organometallic Chemistry
• Photochemistry
• Medicinal Chemistry

Background:

• Cyclometallated Iridium(III) complexes are explored for their photophysical properties and potential therapeutic applications.
• Benzimidazole-based ligands offer tunable electronic and steric properties for metal complex design.
• Understanding structure-activity relationships is crucial for developing effective anticancer agents.

Purpose of the Study:

• To synthesize and characterize a series of cyclometallated Iridium(III) complexes with benzimidazole-based ligands and diverse ancillary diimines.
• To evaluate the photophysical properties, singlet oxygen generation, and cellular uptake of these complexes.
• To assess the in vitro anticancer activity, both in the dark and upon light irradiation, and elucidate their therapeutic mechanisms.

Main Methods:

• Synthesis and characterization of five distinct Iridium(III) complexes.
• Photophysical studies including emission spectroscopy and singlet oxygen generation detection.
• In vitro cytotoxicity assays (dark and phototoxicity) on A549 cancer cells.
• Cellular uptake studies and mechanistic investigations using flow cytometry and NADH oxidation assays.

Main Results:

• Complexes displayed oxygen-sensitive emission, with complexes 1, 4, and 5 generating singlet oxygen.
• Complexes 3 and 5 showed significant dark cytotoxicity and high cellular uptake, acting as chemotherapeutic agents.
• Complex 2 exhibited low dark toxicity, potent phototoxicity upon irradiation, and induced apoptotic cell death via reactive oxygen species (ROS) generation, identifying it as a promising photodynamic therapy (PDT) candidate.

Conclusions:

• The study established clear structure-activity relationships for the synthesized Iridium(III) complexes.
• Complex 2 is highlighted as a potential agent for photodynamic therapy (PDT) due to its photophysical properties and targeted cell death induction.
• Complexes 3 and 5 demonstrate potential as chemotherapeutic agents, offering distinct therapeutic strategies.